Fenphedra slimming pill review

Let’s face it – there are literally hundreds of various weight loss pills on the market. It becomes really difficult to know which one is good and which one is bad for your health. Fenphedra has been attracting a lot of attention latterly, so let’s take a closer look at this diet pill.

What is Fenphedra?

It’s a non-prescription slimming pill that suppresses your appetite and boosts your energy levels. That way you will be able to burn more calories and feel less hungry.

Fenphedra side effects

A lot of consumers have reported side effects with their Fenphedra usage. Some of the most commonly reported side effects are: depression, anxiety, nervousness, headache, nausea, mood swings, inability to sleep properly, and breathing problems.

Is Fenphedra scam?

Many users marked Fenphedra as “scam” for several reasons. Large number of users had difficult time with getting their product delivered to them, where they actually paid the product but never received it.

Then there are dishonest marketing tactics that manufacturers of Fenphedra used. For example, they only display positive reviews of their product on their website and also send bulk spam email messages to people.

A lot of consumers complained that Fenphedra simply didn’t work for them, other than giving them side effects. They did not experience any of the promised benefits – no suppressed appetite, no high energy levels and no weight loss.

Also there is a concern that Fenphedra manufacturers don’t offer money back guarantee and will only give you a refund for unopened packages only.

Is Fenphedra recommended?

Not at all. From all the possible side effects to sending people spam marketing emails, Fenphedra is not a serious diet pill at all. You will be better off by looking for another fat burner.

What is the best alternative?

Speaking of fat burners, take a look at Phen375

Tags:
  • fenphedra reviews from consumers
  • fenphedra
  • fenphedra and depression
  • fenphedra compared to phenphedrine
  • fenphedra reviews

Comments are closed.